OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Dual sodium-glucose cotransporter (SGLT) 1/2 versus pure SGLT2 inhibitors: two distinct drug categories or one class with multiple faces?
Theocharis Koufakis, Michael Doumas, Pantelis Zebekakis, et al.
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 13, pp. 1497-1502
Closed Access | Times Cited: 6
Theocharis Koufakis, Michael Doumas, Pantelis Zebekakis, et al.
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 13, pp. 1497-1502
Closed Access | Times Cited: 6
Showing 6 citing articles:
Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases
Yuan Zeng, Yifan Wu, Qian Zhang, et al.
mBio (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 31
Yuan Zeng, Yifan Wu, Qian Zhang, et al.
mBio (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 31
Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved
Barış Afşar, Rengin Elsürer Afşar
Clinical Nutrition (2023) Vol. 42, Iss. 12, pp. 2338-2352
Closed Access | Times Cited: 13
Barış Afşar, Rengin Elsürer Afşar
Clinical Nutrition (2023) Vol. 42, Iss. 12, pp. 2338-2352
Closed Access | Times Cited: 13
Progenitor Cell Function and Cardiovascular Remodelling Induced by SGLT2 Inhibitors
Theodora M. Stougiannou, Konstantinos Christodoulou, Theocharis Koufakis, et al.
Frontiers in Bioscience-Landmark (2024) Vol. 29, Iss. 4, pp. 145-145
Open Access | Times Cited: 4
Theodora M. Stougiannou, Konstantinos Christodoulou, Theocharis Koufakis, et al.
Frontiers in Bioscience-Landmark (2024) Vol. 29, Iss. 4, pp. 145-145
Open Access | Times Cited: 4
Investigating the place of sodium-glucose cotransporter-2 inhibitors and dual sodium-glucose cotransporter-1 and dual sodium-glucose cotransporter-2 inhibitors in heart failure therapy: a systematic review of the literature
Taylor McKenzie, Genevieve M Hale, Amelia Miner, et al.
Heart Failure Reviews (2024) Vol. 29, Iss. 2, pp. 549-558
Closed Access | Times Cited: 1
Taylor McKenzie, Genevieve M Hale, Amelia Miner, et al.
Heart Failure Reviews (2024) Vol. 29, Iss. 2, pp. 549-558
Closed Access | Times Cited: 1
Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date
Brian Tomlinson, Yanhong Li
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 18, pp. 1937-1947
Closed Access | Times Cited: 2
Brian Tomlinson, Yanhong Li
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 18, pp. 1937-1947
Closed Access | Times Cited: 2
Concomitant use of sodium-glucose co-transporter 2 inhibitors and metformin and the risk of osteomyelitis reporting: a disproportionality analysis based on FAERS database
Jiangfan Wu, Xin Wang, Xiaofang Zhao, et al.
Expert Opinion on Drug Safety (2024)
Open Access
Jiangfan Wu, Xin Wang, Xiaofang Zhao, et al.
Expert Opinion on Drug Safety (2024)
Open Access
